SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Issue 10 (9th August 2019) - Sarafidis, Pantelis; Ferro, Charles J; Morales, Enrique; Ortiz, Alberto; Malyszko, Jolanta; Hojs, Radovan; Khazim, Khaled; Ekart, Robert; Valdivielso, Jose; Fouque, Denis; London, Gérard M; Massy, Ziad; et al.